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Abstract  
Objectives: Willingness-to-pay (WTP) provides a broad assessment of wellbeing, capturing benefits beyond 
health. However, the validity of the approach has been questioned and the evidence relating to the sensitivity of 
WTP to changes in health status is mixed. Using menorrhagia (heavy menstrual bleeding) as a case study, this 
exploratory study assesses the sensitivity to scale of WTP to change in health status as measured by a condition-
specific measure, MMAS, which includes both health and non-health benefits. The relationship between EQ-5D 
and change in health status is also assessed.  
Methods: Baseline EQ-5D and MMAS values were collected from women taking part in a randomised 
controlled trial for pharmaceutical treatment of menorrhagia. Following treatment these measures were 
administered along with a WTP exercise. The relationship between the measures was assessed using spearman’s 
correlation analysis, and the sensitivity to scale of WTP measured by identifying differences in WTP alongside 
differences in MMAS and EQ5D values. 
Results: Our exploratory findings indicated that WTP, and not EQ-5D, was significantly positively correlated 
with change in MMAS, providing some evidence for convergent validity. These findings suggest that WTP is 
capturing the non-health benefits within the MMAS measure. Mean WTP also increased with percentage 
improvements in MMAS, suggesting sensitivity to scale.  
Conclusion: When compared to quality of life measured using the condition-specific MMAS measure, the 
convergent validity and sensitivity to scale of WTP is indicated. The findings suggest that WTP is more 
sensitive to change in MMAS, than with EQ-5D.    
Keywords (2-6) willingness-to-pay, MMAS, convergent validity, EQ-5D, sensitivity to scale 
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Title: Sensitivity to scale of willingness-to-pay within the context of menorrhagia 
 
Introduction 
Contingent valuation is a method for assigning monetary values to non-market goods, such as healthcare 
interventions, for use as an outcome measure within Cost-Benefit Analysis (CBA). Willingness-to-pay (WTP) is 
the most commonly used contingent valuation approach and provides an overall measure of strength of 
preference expressed in monetary terms.  Using this approach, individuals are asked to consider hypothetical 
scenarios that describe both the process and outcome of the health care intervention and asked to state maximum 
WTP for the health care good being valued. Sample average WTP values are typically used as an indication of 
strength of preference and can be directly compared to assess the value of alternative health care interventions. 
In a similar way to how EQ-5D is used to inform the outcome measure for Cost-Utility Analysis (CUA), WTP 
can also be used to inform the outcome for a CBA.  Used in this way, it becomes a generic measure of value for 
treatment or services and is thus weighed against cost to measure overall cost-effectiveness.  Depending on the 
ratio between the incremental difference in costs and benefits (WTP) of alternative treatment options, 
judgements can then be made by decision makers on whether to recommend the treatment/service based on this 
ratio.   WTP encapsulates both health and non-health aspects of wellbeing, the advantages of such an approach 
are ever more recognised, particularly because the National Institute for Health and Care Excellence are now 
also commissioning across public health and social care [1]. Despite this, there are key limitations to the WTP 
approach including the difficulty with contemplating the hypothetical survey scenario, and the lack of well 
defined preferences when individuals are unfamiliar with the goods they are asked to value. The literature also 
refers to evidence on strategic bias and questions about the validity of the approach [2].   
The objective of this exploratory study was to examine the validity of the WTP approach using treatment for 
heavy menstrual bleeding (clinically termed menorrhagia) as a case example. Menorrhagia is a chronic 
condition with episodic symptoms which is known to affect both health and non-health aspects of life. Generic 
quality of life measures, such as EQ-5D and SF-6D, that are focused on health alone are recommended for use 
in healthcare to be used to capture the impact of conditions. The advantage of these generic measures is that 
they enable comparison of effectiveness across different treatment conditions as the outcomes are measured 
using one commensurate unit. An interesting feature of menorrhagia is the condition’s chronic but episodic 
nature as the symptoms occur for approximately one week every month which has implications for the timing of 
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assessment when using generic measures with standard recall periods [3]. In terms of validity, within the context 
of menorrhagia the condition-specific quality of life measure, MMAS (menorrhagia multi-attribute scale 
described in detail below), is considered to be the gold standard measure [4]. Whilst condition-specific measures 
can be more sensitive than generic measures their use in decision-making is limited due to the lack of 
comparability across conditions. There are several types of validity that one can assess including content 
validity (whether all relevant aspects of the condition are considered in the instrument), construct validity 
(determines whether an underlying relationship exists between questions in the instrument and an attribute that 
is measured), and criterion validity (whether one attribute or set of attributes predicts an outcome based on 
information from other attributes) [5;6]. The focus of this paper is construct validity, or more specifically 
convergent validity which is the degree to which two theoretically equivalent measures converge, within the 
context of contingent valuation it is often referred to as sensitivity to scale or scope [7]. 
This question is of theoretical relevance as many studies have shown that WTP demonstrates theoretical validity 
with WTP increasing with income [8], and others have focused on convergent validity with other preference 
elicitation measures such as time trade off (TTO) and standard gamble (SG) [9].  The evidence on convergent 
validity within the healthcare sector and sensitivity to the size of the benefit is mixed [9; 10] and in particular, 
the evidence relating to the sensitivity of WTP to changes in health status [9] is far from conclusive. In theory, 
the respondent’s perception of the value of a treatment should be sensitive to changes in the size of the benefit 
derived from the treatment. For example, WTP demonstrates convergent validity if the WTP increases with a 
perception of greater improvement in treatment benefit. This study presented a unique opportunity to assess the 
sensitivity of WTP longitudinally as both EQ5D and MMAS data were collected at different time points, along 
with WTP. The sensitivity to scale of WTP can therefore be assessed in relation to EQ5D and MMAS over time.    
First, we assessed the change in condition-specific quality of life following treatment for menorrhagia, as 
measured by MMAS, against the WTP for this change in outcome, and second, we assessed the underlying 
relationship between WTP and general health-related quality of life when measured using EQ-5D.   
 
Methods 
We carried out the exploratory study with women who were already participating in the NIHR funded ECLIPSE 
trial (ISRCTN86566246) [11]. Ethical approval was obtained from the National Research Ethics Service 
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Committee South West - Exeter and clinical trial authorisation from the Medicines and Healthcare Regulatory 
Authority. Written consent was obtained from the participants.  
 
Study population 
The ECLIPSE trial is a pragmatic, multicentre, randomised trial, comparing the clinical and cost-effectiveness 
of levonorgestrel-releasing intrauterine device (LNG-IUS) against usual medical treatment in the primary care 
setting [11; 12]. Women between 25 and 50 years of age that presented to their general practitioner (GP) with 
menorrhagia, occurring over at least three consecutive cycles, were randomised to a treatment group by 
telephone or web-based central randomisation service. Women were excluded if they intended to become 
pregnant over the next 5 years, were taking hormone replacement therapy or tamoxifen, had intermenstrual or 
post-coital bleeding or examination suggestive of fibroids (abdominally palpable uterus equivalent in size to 10-
12 weeks’ gestation) or other pathologies, or had contraindications to, or a preference for, LNG-IUS or usual 
medical treatments. The pharmaceutical treatments were either the LNG-IUS (termed Mirena in the 
questionnaire) or usual medical treatment (oral treatment), which can include tranexamic acid, mefenamic acid, 
combined oral contraceptive or depo-provera.  
 
Data collection 
Data were collected at baseline and once symptoms had stabilised with treatment (‘post initial treatment 
effectiveness’). As the study is nested within the ECLIPSE trial, ECLIPSE trial data collection forms were used 
to collect baseline data. For the post initial-treatment effectiveness data collection and for the purposes of this 
study, we adapted the ECLIPSE trial forms by adding an additional WTP question. Both questionnaires were 
sent to women in the ECLIPSE trial for completion.  
 
(1) ECLIPSE trial baseline questionnaire 
As part of the trial follow-up women were asked to complete the condition-specific measure MMAS and the 
generic health related quality of life measure EQ-5D-3L.  The instruments had the following properties: 
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i. MMAS. MMAS is a self-report questionnaire that has six attributes including ‘practical difficulties’, 
‘social life’, ‘psychological health’, ‘physical health and wellbeing’, ‘work/daily routine’ and ‘family 
life/ relationships’. Each attribute has 4 levels ranging from unaffected to severely affected. For 
example, the wording for social life relating to severely affected reads ‘My social life is devastated 
during my cycle. I am unable to make any plans’. The questions refer to “during my cycle” and the 
respondent ticks the level that most accurately reflects their experience. The measure is scored on a 0-
100 scale, with 0 being worst possible state for the condition and 100 being best possible state. Each 
attribute has been weighted according to menorrhagia patients preferences using 21 counters, which are 
considered to be importance points. The visual analogue scale (0-100) is then used to weight the 
relative importance of the levels within the attribute. The weighting for the levels is then multiplied by 
the weighting for the attribute. The overall score is then derived by summing the value of the levels 
ticked by the respondent to provide an overall score between 0-100 [13]. 
 
ii. EQ-5D-3L. EQ-5D is a generic measure of health outcome that can be used across a range of 
conditions. Its five attributes include ‘mobility’, ‘self-care’, ‘usual activities’, ‘pain/discomfort’ and 
‘Anxiety/depression’ The attributes each have 3 levels and the questions are asked with reference to 
“health today”. Responses to the instrument can be used to generate a health-related quality of life 
score referred to as a ‘utility’ value expressed on a scale where 0 represents death, values below zero 
worse than death and 1 indicates full health.  
 
(2) Post-initial treatment effectiveness questionnaire 
The questionnaire booklets that were designed for the purpose of this study were posted in August 2012 to all 
eligible women in the ECLIPSE trial. This time point captured women who were either 2 or 5 years post-initial 
treatment effectiveness, due to the 3 year time period for recruitment into the trial. By post, women received (1) 
a patient information sheet outlining the purpose of the work and; (2) an ‘ex-post’ (post-initial treatment 
effectiveness) questionnaire; and (3) a pre-paid stamped addressed envelope to return the completed 
questionnaire.  
The objective of the ex-post questionnaire was to elicit a WTP value for the pharmaceutical treatment that the 
women were currently taking, either LNG-IUS or oral treatment. In this context therefore, average maximum 
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WTP values were derived after the change in outcome had occurred, from respondents who had experience of 
the condition and experience of the treatment. Hence, WTP was elicited from the ex-post perspective. The WTP 
value therefore reflected the direction and level of change in outcome over time in response to treatment.  It is a 
commonly practiced approach to consider use value when eliciting WTP in healthcare [14;15;16].  
Maximum WTP values were elicited for both LNG-IUS and oral treatment using the self-complete ex-post 
booklet questionnaire. The booklet was similar in design to the trial questionnaire and captured data on 
condition-specific quality of life (MMAS), WTP, socio-demographic details and health-related quality of life 
using the EQ-5D-3L. 
The MMAS was first presented in the questionnaire, followed by questions to determine current and previous 
treatment taken as part of the ECLIPSE trial. Respondents were asked for their maximum monthly out of pocket 
WTP value for their current treatment. The time frame of payment of ‘up until menopause’ was explicitly stated 
to ensure WTP values were not overestimated [17]. To elicit WTP the payment scale elicitation format was used 
as it has a higher completion rate than other methods that can be used in a postal questionnaire [18]. The scale 
range used was £0-£500 and an open-ended option for values greater than £500  was offered. To assess the 
validity of the WTP responses and the respondents understanding of the WTP question, we then asked the 
respondent to outline reasons for their WTP values in an open ended question. This approached enabled an 
assessment of responses as well as providing insight into the way in which the WTP question was interpreted. 
To ensure the WTP values were realistic i.e. within the respondent’s resources, and in line with good practice, a 
reminder was included asking the women to consider the amount that they can actually afford to pay [19].  
 
 Analysis 
For the analysis baseline data were taken from the ECLIPSE trial questionnaire and post-initial treatment 
effectiveness data were from the purposely developed WTP questionnaire. Scores were calculated for the 
baseline MMAS, obtained from the ECLIPSE trial, and the current (‘ex-post’) MMAS score. Similarly, baseline 
and follow-up EQ-5D quality of life score was calculated for every women [20]. Descriptive statistics are 
reported for each measure and a paired t-test was conducted to determine the difference between follow-up and 
baseline values at the 5% level. Cohen’s effect size (mean change divided by standard deviation) is calculated 
for each of the measures where 0.2-0.5 indicates a small change, 0.5-0.8 moderate and >0.8 large [21]. As the 
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assessment of the validity of WTP is the aim of this study, and not the incremental difference between treatment 
arms, the WTP values for both treatments were combined. The CUA and CBA which consider the treatment 
effect by group are presented elsewhere [12;22]. Thus the WTP for overall treatment (both LNG-IUS and oral 
treatment) for menorrhagia is used to assess the convergent validity. The association between WTP and change 
in condition-specific quality of life (MMAS), from baseline to the ex-post values, was first assessed.  Second, 
the association between WTP and change in general health related quality of life as measured by the EQ-5D was 
assessed. Finally, the association of change in MMAS and change in EQ-5D was explored. The associations 
between the measures were assessed by Spearman’s correlation analysis. A Rho value between 0.10-0.29 
indicates a small association, 0.30-0.49 medium association and greater than 0.5 a large association [23]. The 
percentage improvement in MMAS from baseline to current time point was also calculated, using percentage 
improvements (<25%, 26-50%, 51-75% and >75%) to establish the extent to which WTP increased with 
improvement in MMAS from baseline. The Wilcoxon rank-sum test was carried out to identify if the differences 
between the WTP values for each percentage change were significant at the 5% level. The qualitative reasons 
for the WTP values were further analysed and categories generated based on a previous published WTP study 
[14]. The qualitative information was supplemented by exploring the influence of prominent numbers on the 
WTP results. Prominent numbers are those that are typically selected by respondents and include £0,1, 
2,5,10,20,50,100,200,500 and so on [24]. The selection of prominent numbers is thought to be related to the 
respondent’s perception of the difficulty of the task and their knowledge of the intervention [25]. Where 
appropriate GBP is converted to USD using a currency conversion website www.fxexchangerate.com; (£1= 
US$0.665; 2013).  We carried out all data analysis in STATA (v11.0) and Microsoft Excel. 
 
 
Results 
All of the two hundred and seventy-two women who were eligible to complete the questionnaire in the trial 
received a copy. One hundred and sixty-three questionnaires (60%) were received; however 78 of these 
questionnaires were excluded as the women were no longer taking either of the randomised pharmaceutical 
treatments and therefore the WTP section was not applicable to these women. Our intention was to obtain the 
value for either treatment (LNG-IUS or oral treatment) and the question posed in the questionnaire referred to 
‘current treatment’. As these women were either no longer taking any treatment due to menopause or other 
reasons it would not be appropriate to use values for ‘current treatment’. However, the values of those who have 
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crossed over to the other treatment are included to ensure that the values of those who were unhappy with their 
original treatment were included.  
Out of the remaining 85 women who returned the questionnaire and were currently taking one of the randomised 
treatments, 4 (4%) women did not provide a WTP value and MMAS score for their current treatment, and 11 
(13%) protest answers were identified from the qualitative explanations offered for the WTP value. Protest 
responses are defined as an explicit objection to being asked to ‘pay’ for health care and therefore a 
misunderstanding of the hypothetical nature of the exercise and are therefore invalid. These 15 non-responses 
and protest answers were removed from the analysis. It is generally accepted in the literature that qualitative 
information associated with the protest responses should be assessed to determine whether the values are 
genuine WTP values or if the respondent is protesting against the exercise. There is a debate in the literature 
about the inclusion of protest responses [14]. Where protests are identified it has been argued that these should 
not be included in the analysis as they are not valid responses, however, some authors have expressed concerns 
about their exclusion if the characteristics of the excluded and included group are not assessed [14].  There were 
no significant differences between the characteristics of this excluded group to the sample analysed (see online 
supplementary material). In total, 70 respondents gave a WTP value for either LNG-IUS or oral treatment and 
the characteristics of this sample are presented in Table 1. The proportion of respondents that had a household 
income of less than £30,000 (US$45,113) was approximately 50%, which was lower than the national average 
where 65% are below approximately £27,000 (US$40,602) [26]. 
 
Treatment response 
The average maximum WTP for treatment for menorrhagia was approximately £27 (US$41) per month (see 
Table 2). The average combined MMAS score for treatment doubled from approximately 43 at pre-treatment to 
85 following treatment, generating a statistically significant improvement in health status as measured by this 
instrument (p=0.000). According to Cohen’s standardised effect size the mean effect of 1.97 observed on 
MMAS would indicate a large change as the effect size is greater than 0.8. Whilst average EQ-5D values 
increased significantly (p=0.0168) from 0.789 pre-treatment to 0.880 post initial treatment effectiveness, the 
mean effect size of 0.36 indicates a small change using the same Cohen’s criteria (Table 3). Whilst 0.789 pre-
treatment to 0.880 post-initial treatment effectiveness generates a mean effect size of 0.36 which would indicate 
a small change using the same Cohen’s criteria it should be noted that this level of change in EQ-5D would lead 
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to a change in one level of one attribute for example, using the pain attribute a change would be observed from 
some pain to no pain which could be deemed clinically important. 
 
 
Respondent’s understanding of WTP 
Among the 70 women who provided a WTP value, 69 provided a reason for the value. Nine categories of 
reasons for a WTP value were generated from the qualitative information from all of the women, which 
included protests and non-response. The categories of reasons for the sample analysed are presented in Table 4. 
It can be seen that for both LNG-IUS and Oral treatment that ‘R4: affordability’ and ‘R7: effects of treatment’ 
are the most commonly cited reason for a WTP value. In addition to this finding, it can be seen from Figure 1, 
which presents the WTP values for treatment against the number of observations, that the most commonly 
selected WTP values were prominent numbers, those are £10 and £20, which make up 31% and 16% of the 
sample which could indicate difficulty with the WTP exercise or a tendency to round numbers (discussed later).  
 
Associations 
Average maximum WTP were significantly positively correlated with change in MMAS (p=0.025) (Table 5). 
That is, the greater the change in health state, as measured by change in MMAS, the greater the WTP value. 
However, the strength of the relationship is relatively small, generating a rho value of 0.27. In contrast, the 
association between change in EQ-5D and change in MMAS did not show statistical significance (p=0.059), 
despite demonstrating a positive correlation (r=0.23). An unusual, though non-significant result is generated in 
the association between WTP and change in EQ-5D, as a minor negative correlation (r=-0.02) is observed.  
When WTP for percentage change in MMAS is assessed, the mean WTP increases as the change in health status 
increases (from approximately £16 to £63 (US$25 to US$95)). Whilst the mean values would suggest that WTP 
would continue to increase the greater the change in health status, the median values illustrate the skewness of 
the data but still demonstrate an increase in WTP as health status improves (Table 6). The significance tests 
show the WTP values between ‘<25%’ and ‘51%-75%’ to be significantly increased as percentage change in 
MMAS increases (p= 0.033; p<0.05).  
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Discussion 
In this exploratory study we aimed to assess the convergent validity of WTP within the context of menorrhagia 
by comparing change in the condition-specific measure (MMAS) to; (1)  change in WTP and (2) the generic 
health-related quality of life measure, EQ-5D-3L. Overall, our findings suggest the convergent validity of WTP 
as it behaves as would intuitvely be expected in response to change in health status, as measured by MMAS. 
Specifically, following treatment, WTP increases with a greater improvement in treatment benefit, and the 
correlation between the change in condition-specific MMAS and WTP suggests statistical significance.  
An association between MMAS and the generic measure, EQ-5D, was not observed as the change in EQ-5D 
scores before and after treatment was not significantly associated with the equivalent change in MMAS.  This 
result suggests that WTP is more sensitive to change in the condition-specific measure (MMAS), than the 
generic measure (EQ-5D). We hypothesise that this finding is attributed to the EQ-5D instrument being 
designed as a generic-health related quality of life measure, which is not focussed specifically on menorrhagia. 
We suggest that WTP is more sensitive given it has the potential to measure both health and non-health aspects 
of quality of life that are important to women who suffer with menorrhagia, which are also encompassed by the 
MMAS measure.  
Qualitative reasons for the WTP responses provided a further opportunity to assess the reliability of the WTP 
values. The analyses of the reasons confirmed that respondents were considering the ‘value’ of the treatment as 
was theoretically expected. These values are therefore reflective of what the theory says people consider when 
completing WTP exercises. However, the selection of prominent numbers could be related to the perceived 
difficulty of the task [25] where respondents provide less precise values when they do not feel they have 
adequate knowledge of the good being valued [24]. In this study the WTP values were elicited from the ex-post 
perspective where respondents have experience of, and are knowledgeable about, the treatments and despite this, 
prominent numbers were most commonly selected. This indicates that although respondents stated ‘true’ WTP 
values as confirmed by the qualitative responses, the selection of prominent numbers alludes to the WTP 
elicitation task being difficult to complete.  
Finally, as there are several possible approaches for eliciting WTP, the method used in the analysis reported here 
requires some justification. With respect to the WTP question the time period ‘up until menopause’ seemed 
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intuitive given that menorrhagia ceases at menopause and the scale of £0-£500 was thought most suitable, given 
that the questionnaire asked respondents to provide a monthly WTP value. The monthly payment time frame 
was used because women generally pay monthly (or every three months) for prescriptions for menorrhagia, for 
sanitary protection and they experience the benefits of treatment on a monthly basis. The out of pocket payment 
vehicle was deemed appropriate for this context because whilst the full price for treatment is not paid in the UK, 
patients do make an out of pocket payment  for prescriptions for  oral treatment in the UK. Although this private 
payment does not exist for LNG-IUS, the existence of private payment within this context is likely to minimise 
the issue of hypothetical bias. 
To our knowledge, this is the first study to assess the convergent validity of WTP against a change in condition-
specific quality of life measure in menorrhagia. It is also the first to compare the correlation of WTP and change 
in EQ-5D with a condition-specific quality of life measure.  
A limitation of this exploratory study is the sample size used. Given that the significant difference was observed 
between the two percentage change categories with the greatest number of observations, it is likely that the 
remaining categories were not found to be significant due to the limited sample size for the groups ‘26-50%’ 
and ‘>75%’. Thus there may not have been sufficient power to detect a significant difference between these 
groups. The findings from this exploratory study however can be used to inform future sample size calculations 
for subsequent WTP studies in the area. Prior to this study it was not readily possible to calculate sample size 
requirements as a-priori data on the distribution of WTP values for the LNG-IUS or Oral treatment were not 
available [27]. This study therefore enables researchers to identify the number and range of responses given to 
determine how many respondents are required to detect a certain difference in WTP across treatments i.e. the 
WTP value that constitutes a meaningful difference in improvements from baseline or between treatments.  
To our knowledge no other study has assessed the sensitivity to scale of WTP according to a longitudinal 
change in outcome measured by a condition-specific measure. Other related studies have however  assessed the 
relative sensitivity of WTP  and time trade off (TTO) for changes in described dimensions of health states, and 
have tentatively suggested that WTP is sensitive to change in different levels of health within the same 
dimension [9]. The sensitivity of (ex-ante) WTP with a condition-specific measure at one time point has also 
been explored [28; 29]. Radtke et al [28] assessed the relationship between WTP, EQ-5D and a condition 
specific measure for vitiligo; and Schiffner et al [29] assessed the sensitivity of WTP and TTO with a condition-
specific measure for psoriasis. Baseline EQ-5D (or TTO) and condition-specific scores for current health state 
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were identified and hypothetical WTP values were elicited for a cure. Both studies found that WTP had a 
significant correlation with the condition-specific measure and Radtke et al [28] also showed WTP and EQ-5D 
to have negative correlation.   
Other psychometric properties of WTP and EQ-5D in menorrhagia have also been explored. A review of 
psychometric properties of measures used in menorrhagia [3] identified four key studies. One study assessed the 
consistency of responses of WTP from women with menorrhagia and found a lack of external reliability of WTP 
[30]. The second found EQ-5D to be unsuitable for patients with menorrhagia [4]. In the third, MMAS was 
statistically associated with changes in satisfaction post-initial treatment effectiveness whilst EQ-5D was not 
[31]. Finally, a lack of sensitivity of EQ-5D to changes in quality of life associated with menorrhagia was 
observed [32]. 
Further research is required to consolidate our findings using a larger sample size, the requirements for which 
can now be derived based on our study. Additional research could explore the convergent validity of other 
methods of valuation such as SF-6D in such a condition, assessing changes in SF-6D in relation to WTP and 
MMAS to determine the extent to which SF-6D reflects changes in MMAS. This exploratory study suggests that 
there is the potential, and a benefit, to the use of WTP in chronic conditions with episodic symptoms which 
impact on health and non-health aspects of life. 
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Tables 
Table 1. Sample characteristics of WTP respondents 
 
Variable Treatment 
(n=70) 
Expected age of menopause (yrs) [SD] 53.80 [2.50] 
Age [SD] 48.09 [3.93] 
Marital status (%)  
Married or living with partner 53 (76%) 
Not  17 (24%) 
Employment status (%)  
Employed (FT)/(PT) 56 (80%) 
Not 14 (20%) 
Household income (%)  
Less than £20,000 (<$30,075) 22 (32%) 
£20,001-30,000 ($30,077 - $45,113) 14 (20%) 
£30,001-40,000 ($45,114 - $60,150) 10 (14%) 
£40,001-50,000 ($60,152 - $75,188) 9 (13%) 
More than £50,000 (>$75,189) 13 (20%) 
Main earner (%)  
Yes 32 (46%) 
No 37 (54%) 
FT: full-time, PT: part-time, SD: standard deviation. (US$) 
 
 
 
 
 
 
 
 
16 
 
 
 
 
 
 
 
Table 2. Descriptive statistics for WTP 
 Valid responses Mean (Median) [$] Min-Max [$] SD [$] 
WTP 70 £26.99 (£10) 
[$40.59  ($15)] 
£0-£500 
[$0-$752] 
£60.73 
[$91.32] 
SD, standard deviation; WTP, willingness to pay. (US$) 
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Table 3. Average scores for the instruments 
 Mean MMAS [SD] EQ-5D [SD] WTP ($) 
Baseline (n=70) 43.23[21.22] 0.789 [0.250]  
Post-initial treatment 
effectiveness (n=70) 
 
85.00 [23.15] 0.880 [0.215] £26.99 ($40.59) 
Change (n=70) 41.77 [32.03] 0.09 [0.31]  
MMAS, Menorrhagia multi-attribute scale; SD, standard deviation; WTP, willingness to pay 
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Table 4. Explanation given for WTP value (sample analysed, ex-post) 
Category Explanation Total  
n (%) 
   
R2 Subject expressed difficulty estimating WTP owing to: 
- Difficult to answer 
- Cannot put a price on healthcare 
8 (7%) 
R3 WTP based on nominal amount 
- Arbitrary sum/ guess/ out of thin air 
1 (0.9%) 
R4 WTP reflects ability to pay (affordability) 
- Maximum affordable amount given current 
situation  
37 (35%) 
R5 WTP reflects reasonable value 
- NHS should pay but this is a reasonable limit 
8 (7%) 
R6 WTP reflects cost of treatment 
- Attempted to estimate cost 
- Used a comparator such as prescription costs 
5 (5%) 
R7 WTP reflects effect of treatment 
- In terms of effectiveness outcomes 
- In terms of process utility 
30 (28%) 
   
R9 Related to cost of sanitary wear 
- Washing clothes/wipes/painkillers 
13 (12%) 
R10 Misunderstood exercise but provided WTP value 5 (5%) 
Total  107* 
NHS; National Health Service, WTP; willingness-to-pay. *Some respondents gave more than one reason for 
their WTP value. Categories R1 and R8 were related to protest responses and are deleted from the table as they 
were not included in the sample analysed 
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Table 5. Associations between measures  
 Change in MMAS 
(rho) 
WTP  
(rho) 
Change in EQ-5D  
(rho) 
Change in MMAS 1.0000   
WTP 0.2674* 1.000  
Change in EQ-5D 0.2265 -0.0158 1.000 
*P= 0.0252 ( <0.05) MMAS; menorrhagia multi-attribute scale, WTP; willingness-to-pay 
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Table 6. Mean WTP against percentage improvement in MMAS 
% change 
in MMAS 
Mean  
MMAS [SD] 
No. 
obs 
Mean WTP [SD] 
($) 
Median 
($)  
Min – Max WTP ($) 
<25%  1.27 [12.82] 21 £16.29 [£17.97] ($24.50) £10 ($15) £0 - £50 ($0-75) 
26% - 50% 36.13 [8.3] 14 £20.86 [£24.65] ($31.37) £10 ($15) £6 - £100 ($9-$150) 
51% - 75% 60.95 [9.04] 24 £23.38 [£20.63] ($35.16) £20 ($30) £8 -£100 ($5-$150) 
>75%  84.44 [10.00] 11 £63.09 [£145.86] ($94.87) £20 ($30) £0 - £500 ($0-$752) 
MMAS; menorrhagia multi-attribute scale, SD, standard deviation; WTP; willingness-to-pay. (US$) 
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Figure Legends 
Figure 1. Frequency of WTP values 
 
